JP7736678B2 - Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド - Google Patents
Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミドInfo
- Publication number
- JP7736678B2 JP7736678B2 JP2022522680A JP2022522680A JP7736678B2 JP 7736678 B2 JP7736678 B2 JP 7736678B2 JP 2022522680 A JP2022522680 A JP 2022522680A JP 2022522680 A JP2022522680 A JP 2022522680A JP 7736678 B2 JP7736678 B2 JP 7736678B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methyl
- dimethyl
- dioxo
- biphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962915779P | 2019-10-16 | 2019-10-16 | |
| US62/915,779 | 2019-10-16 | ||
| US202063042796P | 2020-06-23 | 2020-06-23 | |
| US63/042,796 | 2020-06-23 | ||
| US202063057460P | 2020-07-28 | 2020-07-28 | |
| US63/057,460 | 2020-07-28 | ||
| PCT/US2020/055672 WO2021076691A1 (en) | 2019-10-16 | 2020-10-15 | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022551973A JP2022551973A (ja) | 2022-12-14 |
| JP2022551973A5 JP2022551973A5 (enExample) | 2023-10-24 |
| JP7736678B2 true JP7736678B2 (ja) | 2025-09-09 |
Family
ID=75538873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522680A Active JP7736678B2 (ja) | 2019-10-16 | 2020-10-15 | Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11713307B2 (enExample) |
| EP (1) | EP4045036B1 (enExample) |
| JP (1) | JP7736678B2 (enExample) |
| KR (1) | KR20220084119A (enExample) |
| CN (1) | CN114585359B (enExample) |
| AU (1) | AU2020368393B2 (enExample) |
| BR (1) | BR112022006018A2 (enExample) |
| CL (1) | CL2022000956A1 (enExample) |
| CO (1) | CO2022004723A2 (enExample) |
| CR (1) | CR20220215A (enExample) |
| EC (1) | ECSP22038478A (enExample) |
| ES (1) | ES3068390T3 (enExample) |
| IL (1) | IL291642A (enExample) |
| MX (1) | MX427916B (enExample) |
| PE (1) | PE20221445A1 (enExample) |
| PH (1) | PH12022550876A1 (enExample) |
| TW (1) | TWI902711B (enExample) |
| WO (1) | WO2021076691A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019165043A2 (en) | 2018-02-22 | 2019-08-29 | Chemocentryx, Inc. | Indane-amines as pd-l1 antagonists |
| BR112021022659A2 (pt) | 2019-05-15 | 2022-03-29 | Chemocentryx Inc | Compostos triarílicos para o tratamento de doenças pd-l1 |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| ES3068390T3 (en) | 2019-10-16 | 2026-05-29 | Chemocentryx Inc | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| AU2020368392B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| TW202216694A (zh) * | 2020-06-23 | 2022-05-01 | 美商卡默森屈有限公司 | 使用雜芳基-聯苯醯胺衍生物治療癌症之方法 |
| MX2023014754A (es) | 2021-06-18 | 2024-02-12 | Aligos Therapeutics Inc | Métodos y composiciones dirigidos a pd-l1. |
| CN119212987A (zh) | 2021-12-16 | 2024-12-27 | 安力高医药股份有限公司 | 用于靶向pd-l1的方法和组合物 |
| CN115010658B (zh) * | 2022-05-11 | 2023-06-27 | 南方医科大学 | 一种化合物及其制备方法与应用 |
| AU2024209359A1 (en) * | 2023-01-20 | 2025-07-03 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| WO2025015063A1 (en) * | 2023-07-13 | 2025-01-16 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
| WO2025174835A1 (en) * | 2024-02-15 | 2025-08-21 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010024783A1 (en) | 2008-08-27 | 2010-03-04 | Agency For Science, Technology And Research | Biarylrhodanine and pyridylrhodanine compounds and their use |
| WO2018119224A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| WO2018119266A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| JP2019508504A (ja) | 2016-03-11 | 2019-03-28 | フィンブリオン セラピューティックス， インコーポレイテッドＦｉｍｂｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 疾病の処置に有用なｃ−グリコシド化合物 |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2021063404A1 (zh) | 2019-09-30 | 2021-04-08 | 南京明德新药研发有限公司 | 作为pd-1/pd-l1小分子抑制剂的化合物及其应用 |
| JP2022531970A (ja) | 2019-05-15 | 2022-07-12 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患治療用のトリアリール化合物 |
Family Cites Families (136)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| GB9604926D0 (en) | 1996-03-08 | 1996-05-08 | Sandoz Ltd | Organic compounds |
| DK1531822T3 (da) | 2002-06-12 | 2009-12-07 | Chemocentryx Inc | 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| AU2003298661B2 (en) | 2002-11-18 | 2007-05-10 | Chemocentryx, Inc. | Aryl sulfonamides |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| JP2007537275A (ja) | 2004-05-12 | 2007-12-20 | ケモセントリックス， インコーポレイテッド | アリールスルホンアミド |
| AU2006204750C1 (en) | 2005-01-14 | 2012-11-01 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US7622583B2 (en) | 2005-01-14 | 2009-11-24 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2 |
| US20070010523A1 (en) | 2005-06-22 | 2007-01-11 | Chemocentryx, Inc. | Azaindazole compounds and methods of use |
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| ATE486875T1 (de) | 2005-11-10 | 2010-11-15 | Chemocentryx Inc | Substituierte chinolone und verwendungsverfahren |
| WO2007115232A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| PT2402319T (pt) | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| US20100234364A1 (en) | 2006-07-14 | 2010-09-16 | Arindrajit Basak | Ccr2 inhibitors and methods of use thereof |
| PL2046762T3 (pl) | 2006-07-14 | 2011-07-29 | Chemocentryx Inc | Triazolilofenylobenzenosulfonamidy |
| CN101511800B (zh) | 2006-07-14 | 2013-02-27 | 坎莫森特里克斯公司 | 三唑基苯基苯磺酰胺 |
| EP2155712B1 (en) | 2007-05-22 | 2016-09-07 | ChemoCentryx, Inc. | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines |
| US7776877B2 (en) | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| CA2692761C (en) | 2007-07-12 | 2013-04-30 | Chemocentryx, Inc. | Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treament of inflammation |
| CN102159213B (zh) | 2008-09-11 | 2015-05-27 | 凯莫森特里克斯股份有限公司 | 4-氨基-3-(咪唑基)-吡唑并[3,4-b]嘧啶 |
| CA2742306A1 (en) | 2008-11-03 | 2010-05-06 | Chemocentryx, Inc. | Compounds for the treatment of osteoporosis and cancers |
| KR101701367B1 (ko) | 2008-11-04 | 2017-02-02 | 케모센트릭스, 인크. | Ｃｘｃｒ７의 모듈레이터 |
| JP5819730B2 (ja) | 2008-12-22 | 2015-11-24 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| US8293925B2 (en) | 2009-09-21 | 2012-10-23 | Chemocentryx, Inc. | Pyrrolidinone carboxamide derivatives |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| EA023521B1 (ru) | 2011-11-14 | 2016-06-30 | Сефалон, Инк. | ПРОИЗВОДНЫЕ УРАЦИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ AXL И c-MET КИНАЗЫ |
| US8835419B2 (en) | 2011-12-01 | 2014-09-16 | Chemocentryx, Inc. | Substituted anilines as CCR(4) antagonists |
| KR102031846B1 (ko) | 2011-12-01 | 2019-10-14 | 케모센트릭스, 인크. | Ｃｃｒ(4) 길항제로서의 치환된 벤즈이미다졸 및 벤조피라졸 |
| EP2788000B1 (en) | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| DK2820006T3 (da) * | 2012-02-29 | 2017-11-06 | Chemocentryx Inc | Pyrazol-1-yl benzen sulfonamider som ccr9 antagonister |
| AU2013352304C1 (en) | 2012-11-29 | 2018-03-22 | Chemocentryx, Inc. | CXCR7 antagonists |
| EP2928474B1 (en) | 2012-12-07 | 2018-11-14 | ChemoCentryx, Inc. | Diazole lactams |
| JP6306607B2 (ja) | 2012-12-21 | 2018-04-04 | ケモセントリックス，インコーポレイティド | ジアゾールアミド |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| MX2016002544A (es) | 2013-09-04 | 2016-06-17 | Squibb Bristol Myers Co | Compuestos utiles como inmunomoduladores. |
| TR201811077T4 (tr) | 2013-09-06 | 2018-08-27 | Aurigene Discovery Tech Ltd | İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri. |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| CN105960237B (zh) | 2013-12-02 | 2020-03-31 | 凯莫森特里克斯股份有限公司 | Ccr6化合物 |
| GB201322334D0 (en) | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | Maleimide derivatives as modulators of WNT pathway |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP6767096B2 (ja) | 2014-12-11 | 2020-10-14 | リティックス バイオファーマ エイエス | 免疫チェックポイント阻害剤の組み合わせ |
| CN107108526A (zh) | 2015-01-22 | 2017-08-29 | R·P·小沃勒尔 | 双功能化合物及用于降低尿酸水平的用途 |
| EP3294728A1 (en) | 2015-05-13 | 2018-03-21 | Selvita S.A. | Substituted quinoxaline derivatives |
| RU2726206C2 (ru) | 2015-05-21 | 2020-07-09 | Кемосентрикс, Инк. | Модуляторы ccr2 |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| NL1041468B1 (en) | 2015-09-08 | 2017-03-22 | Bosch Gmbh Robert | Metal ring component of a drive belt for a continuously variable transmisson. |
| US10745382B2 (en) | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| ES2916874T3 (es) * | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| CA3009474A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3190103A1 (en) | 2016-01-08 | 2017-07-12 | Rijksuniversiteit Groningen | Inhibitors of the pd-1/pd-l1 protein/protein interaction |
| BR112018014666B1 (pt) | 2016-01-20 | 2024-01-02 | Chemocentryx, Inc | Compostos de 2-oxindol, seu uso e composição farmacêutica |
| SG11201808625QA (en) | 2016-04-04 | 2018-10-30 | Chemocentryx Inc | SOLUBLE C5aR ANTAGONISTS |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US10882833B2 (en) | 2016-05-23 | 2021-01-05 | Institute Of Materia Medica, Chinese Academy Of Medical Sciences | Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| EP3474845B1 (en) | 2016-06-27 | 2024-03-20 | ChemoCentryx, Inc. | Immunomodulator compounds |
| AU2017294231B2 (en) | 2016-07-05 | 2021-09-09 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
| CN109689640B (zh) | 2016-07-08 | 2022-01-04 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US10144706B2 (en) | 2016-09-01 | 2018-12-04 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| WO2018045142A1 (en) | 2016-09-02 | 2018-03-08 | Polaris Pharmaceuticals, Inc. | Immune checkpoint inhibitors, compositions and methods thereof |
| KR102599339B1 (ko) | 2016-12-20 | 2023-11-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제로서 유용한 화합물 |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| CN106674136B (zh) | 2016-12-23 | 2019-07-02 | 中国医科大学 | 嘧啶类抗肿瘤化合物及其制备方法 |
| US10654815B2 (en) | 2016-12-29 | 2020-05-19 | Shenzhen Chipscreen Biosciences Co., Ltd. | Urea compound and preparation method and application thereof |
| CN108395443B (zh) | 2017-02-04 | 2021-05-04 | 广州丹康医药生物有限公司 | 抑制程序性死亡受体配体1的环状化合物及其用途 |
| JP7150745B2 (ja) | 2017-03-27 | 2022-10-11 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤としての置換イソキノリン誘導体 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| TW201841896A (zh) | 2017-04-26 | 2018-12-01 | 大陸商南京聖和藥業股份有限公司 | 作為pd—l1抑制劑的雜環類化合物 |
| CN108863963B (zh) | 2017-05-08 | 2022-05-27 | 南京圣和药物研发有限公司 | 作为pd-l1抑制剂的杂环类化合物 |
| JP7141129B2 (ja) | 2017-05-31 | 2022-09-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａ阻害剤としての５－５融合環 |
| KR102638253B1 (ko) | 2017-05-31 | 2024-02-16 | 케모센트릭스, 인크. | C5a 억제제로서의 6-5 융합 고리 |
| HUE058353T2 (hu) | 2017-07-10 | 2022-07-28 | Medibiofarma S L | Új heteroaril-amid származékok mint a hiszton-dezacetiláz 1 és 2 (HDAC1-2) szelektív inhibitorai |
| US10919852B2 (en) | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
| KR102670486B1 (ko) | 2017-08-08 | 2024-05-28 | 케모센트릭스, 인크. | 마크로사이클릭 면역조절제 |
| CN109400522B (zh) | 2017-08-18 | 2023-04-28 | 上海轶诺药业有限公司 | 一种具有pd-l1抑制活性的化合物、其制备方法及用途 |
| EP3687525B1 (en) | 2017-09-25 | 2025-10-29 | ChemoCentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| US20190275015A1 (en) | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
| EP3692053A1 (en) | 2017-10-03 | 2020-08-12 | Bristol-Myers Squibb Company | Immunomodulators |
| WO2019074241A1 (ko) | 2017-10-11 | 2019-04-18 | 정원혁 | 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제 |
| CN109665968B (zh) | 2017-10-16 | 2022-02-22 | 四川科伦博泰生物医药股份有限公司 | 并环化合物及其制备方法和用途 |
| CN109678796B (zh) | 2017-10-19 | 2023-01-10 | 上海长森药业有限公司 | Pd-1/pd-l1小分子抑制剂及其制备方法和用途 |
| CN109721527B (zh) | 2017-10-27 | 2024-03-12 | 广州丹康医药生物有限公司 | 一种新型抗pd-l1化合物、其应用及含其的组合物 |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| WO2019120297A1 (zh) | 2017-12-22 | 2019-06-27 | 上海海雁医药科技有限公司 | 免疫调节剂及其制法与医药上的用途 |
| KR102666727B1 (ko) | 2017-12-29 | 2024-05-21 | 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. | 방향족 비닐 또는 방향족 에틸계 유도체, 그의 제조방법, 중간체, 약물조성물 및 용도 |
| US11414418B2 (en) | 2018-01-23 | 2022-08-16 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| AU2019214089B2 (en) | 2018-02-05 | 2021-02-11 | Abbisko Therapeutics Co., Ltd. | Biaryl derivative, preparation method therefor and pharmaceutical use thereof |
| WO2019165043A2 (en) | 2018-02-22 | 2019-08-29 | Chemocentryx, Inc. | Indane-amines as pd-l1 antagonists |
| US11578054B2 (en) | 2018-03-01 | 2023-02-14 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| WO2019174533A1 (zh) | 2018-03-13 | 2019-09-19 | 广东东阳光药业有限公司 | Pd-1/pd-l1类小分子抑制剂及其在药物中的应用 |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| US20210040118A1 (en) | 2018-04-03 | 2021-02-11 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| CN112752756B (zh) | 2018-05-11 | 2024-06-25 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| CN111886219B (zh) | 2018-07-11 | 2023-04-25 | 上海和誉生物医药科技有限公司 | 免疫抑制剂及其制备方法和在药学上的应用 |
| CN112384500B (zh) | 2018-07-12 | 2024-05-14 | 贝达药业股份有限公司 | 免疫调节剂及其组合物和制备方法 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| WO2020015717A1 (en) | 2018-07-19 | 2020-01-23 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| WO2020015716A1 (en) | 2018-07-19 | 2020-01-23 | Betta Pharmaceuticals Co., Ltd | Immunomodulators, compositions and methods thereof |
| EP3831823A4 (en) | 2018-08-01 | 2022-04-27 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION |
| US20210236476A1 (en) | 2018-08-29 | 2021-08-05 | Chemocentryx, Inc. | Methods of treating cancer with small molecule pd-l1 inhibitors |
| EA202091694A1 (ru) | 2018-10-17 | 2021-02-10 | Джилид Сайэнс, Инк. | Ингибиторы pd-1/pd-l1 |
| CN109336857A (zh) | 2018-11-13 | 2019-02-15 | 南方医科大学 | 一种含取代联苯的黄酮及其应用 |
| CN109438263A (zh) | 2018-11-28 | 2019-03-08 | 南方医科大学 | 一种含取代联苯的萘及其应用 |
| CN109503546A (zh) | 2019-01-10 | 2019-03-22 | 南方医科大学 | 一种间苯二酚二苯甲醚及其应用 |
| CN109776377B (zh) | 2019-02-01 | 2021-08-24 | 沈阳药科大学 | 吲哚啉类化合物及其制备方法和应用 |
| US20200297708A1 (en) | 2019-03-19 | 2020-09-24 | Chemocentryx, Inc. | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor |
| CN109776445B (zh) | 2019-03-28 | 2022-12-06 | 中国药科大学 | 苯并噁二唑类化合物及其制备方法和医药用途 |
| CN110200959A (zh) | 2019-05-30 | 2019-09-06 | 天津科技大学 | 一种黄酮类化合物的应用 |
| CN110128415B (zh) | 2019-05-31 | 2022-03-25 | 沈阳药科大学 | 用作免疫调节剂的吲哚啉类化合物及其制备方法 |
| KR102841588B1 (ko) | 2019-06-20 | 2025-08-01 | 케모센트릭스, 인크. | Pd-l1 질환의 치료를 위한 화합물 |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| AU2020368392B2 (en) | 2019-10-16 | 2026-01-08 | Chemocentryx, Inc. | Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases |
| BR112022007284A2 (pt) | 2019-10-16 | 2022-07-05 | Morphic Therapeutic Inc | Inibição de integrina humana alpha-4 beta-7 |
| ES3068390T3 (en) | 2019-10-16 | 2026-05-29 | Chemocentryx Inc | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| TW202216694A (zh) | 2020-06-23 | 2022-05-01 | 美商卡默森屈有限公司 | 使用雜芳基-聯苯醯胺衍生物治療癌症之方法 |
-
2020
- 2020-10-15 ES ES20877065T patent/ES3068390T3/es active Active
- 2020-10-15 KR KR1020227016263A patent/KR20220084119A/ko active Pending
- 2020-10-15 BR BR112022006018A patent/BR112022006018A2/pt unknown
- 2020-10-15 PE PE2022000616A patent/PE20221445A1/es unknown
- 2020-10-15 EP EP20877065.1A patent/EP4045036B1/en active Active
- 2020-10-15 CR CR20220215A patent/CR20220215A/es unknown
- 2020-10-15 PH PH1/2022/550876A patent/PH12022550876A1/en unknown
- 2020-10-15 MX MX2022004451A patent/MX427916B/es unknown
- 2020-10-15 WO PCT/US2020/055672 patent/WO2021076691A1/en not_active Ceased
- 2020-10-15 US US17/071,077 patent/US11713307B2/en active Active
- 2020-10-15 CN CN202080073061.4A patent/CN114585359B/zh active Active
- 2020-10-15 JP JP2022522680A patent/JP7736678B2/ja active Active
- 2020-10-15 AU AU2020368393A patent/AU2020368393B2/en active Active
- 2020-10-16 TW TW109135946A patent/TWI902711B/zh active
-
2022
- 2022-03-23 IL IL291642A patent/IL291642A/en unknown
- 2022-04-13 CO CONC2022/0004723A patent/CO2022004723A2/es unknown
- 2022-04-14 CL CL2022000956A patent/CL2022000956A1/es unknown
- 2022-05-13 EC ECSENADI202238478A patent/ECSP22038478A/es unknown
-
2023
- 2023-06-12 US US18/333,262 patent/US12497383B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010024783A1 (en) | 2008-08-27 | 2010-03-04 | Agency For Science, Technology And Research | Biarylrhodanine and pyridylrhodanine compounds and their use |
| JP2019508504A (ja) | 2016-03-11 | 2019-03-28 | フィンブリオン セラピューティックス， インコーポレイテッドＦｉｍｂｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 疾病の処置に有用なｃ−グリコシド化合物 |
| WO2018119224A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| WO2018119266A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| JP2022531970A (ja) | 2019-05-15 | 2022-07-12 | ケモセントリックス，インコーポレイティド | Ｐｄ－ｌ１疾患治療用のトリアリール化合物 |
| WO2021063404A1 (zh) | 2019-09-30 | 2021-04-08 | 南京明德新药研发有限公司 | 作为pd-1/pd-l1小分子抑制剂的化合物及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| 鈴木 章，鈴木－宮浦カップリング（ＳＭＣ）反応の問題点，ＴＣＩメール，2009年，No.142，2-21 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021076691A1 (en) | 2021-04-22 |
| PH12022550876A1 (en) | 2023-03-27 |
| EP4045036B1 (en) | 2026-03-04 |
| TWI902711B (zh) | 2025-11-01 |
| JP2022551973A (ja) | 2022-12-14 |
| US12497383B2 (en) | 2025-12-16 |
| CA3152329A1 (en) | 2021-04-22 |
| EP4045036A1 (en) | 2022-08-24 |
| BR112022006018A2 (pt) | 2022-07-12 |
| MX427916B (es) | 2025-10-13 |
| AU2020368393B2 (en) | 2026-01-08 |
| CO2022004723A2 (es) | 2022-04-29 |
| CN114585359B (zh) | 2025-08-12 |
| KR20220084119A (ko) | 2022-06-21 |
| AU2020368393A1 (en) | 2022-04-21 |
| US20210130325A1 (en) | 2021-05-06 |
| US11713307B2 (en) | 2023-08-01 |
| CN114585359A (zh) | 2022-06-03 |
| MX2022004451A (es) | 2022-05-03 |
| ECSP22038478A (es) | 2022-06-30 |
| ES3068390T3 (en) | 2026-05-29 |
| EP4045036C0 (en) | 2026-03-04 |
| IL291642A (en) | 2022-05-01 |
| CR20220215A (es) | 2022-09-14 |
| CL2022000956A1 (es) | 2023-01-13 |
| PE20221445A1 (es) | 2022-09-21 |
| EP4045036A4 (en) | 2023-11-15 |
| US20230322731A1 (en) | 2023-10-12 |
| TW202128651A (zh) | 2021-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020276277B2 (en) | Triaryl compounds for treatment of PD-L1 diseases | |
| US12497383B2 (en) | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | |
| JP7686634B2 (ja) | Ｐｄ－ｌ１疾患の治療のためのヘテロアリール－ビフェニルアミン | |
| KR102401963B1 (ko) | 면역조절제 화합물 | |
| JP2022536845A (ja) | Ｐｄ－ｌ１疾患の治療のための化合物 | |
| CA3152329C (en) | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases | |
| RU2848051C1 (ru) | Гетероарилбифенил амиды для лечения pd-l1 заболеваний | |
| RU2837843C1 (ru) | Гетероарил-бифенил амины для лечения pd-l1 заболеваний | |
| RU2840345C2 (ru) | Триарильные соединения для лечения pd-l1 заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231013 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231013 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240919 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241001 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250401 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250807 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250819 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250828 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7736678 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |